How I use genomics and BTK inhibitors in the treatment of WM

Key Findings

• ●Genomics-guided treatment selection in WM
• ●MYD88 and CXCR4 genotyping informs BTK inhibitor choice
• ●MYD88-WT patients may benefit from alternative approaches

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works